Cellectis, a clinical-stage biotech company specializing in gene-editing therapies, announced it will report its financial results for the first quarter of 2026 on May 11, after the US market closes. The company, known for its allogeneic CAR T-cell therapies for cancer and gene therapy platforms, will publish the results on its website but will not hold a conference call. Investors can direct questions to the company's investor relations team. This update is important as it provides insight into the company's financial health and progress in its pioneering gene-editing treatments.
YieldMax ETFs announced weekly distributions for their Group 1 ETFs, with distribution rates ranging from 26.17% to 60.34% annualized. These ETFs cover sectors like semiconductors, AI & tech, crypto, metals, and covered call strategies. Distributions...
The global ultrasonic aspirator market, valued at $194 million in 2025, is projected to grow at a CAGR of 6.87% to reach $376 million by 2035. Growth is fueled by increased use in neurosurgery, orthopedic, and minimally invasive surgeries, driven by ...
MEXC's RealStocks platform, launched in June 2026, saw SpaceX (SPCX) capture nearly 30% of trading volume and user activity, marking it as the most popular stock among over 7,000 US stocks and ETFs available. AI-related stocks collectively accounted ...
The SCHD ETF currently offers a 3.3% yield and is on track to complete its 15th consecutive year of dividend increases in 2026. This consistent dividend growth highlights SCHD's appeal for income-focused investors seeking reliable payouts. Maintainin...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.26% ownership stake in Prologis Inc, totaling 11,789,090 shares as of July 27, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, indicating a significant investment po...
